Centre National De La Recherche Scientifique

Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Université Pierre Et Marie Curie (Paris Vi)

Commissariat a L'energie Atomique

Université Joseph Fourier

Université Grenoble Alpes

Jean-Claude Florent

David Grierson

Ludger Johannes

Sylvie Robine

Jacky Roger

Philipe Maillard

Chi-Hung N'Guyen

Andreï Popov

Aurélie Juhem

Chi-Hung N'guyen

Aurelie Juhem

Andrei Popov

The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer.

Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same

The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gbreceptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein

[object Object]

Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

The present invention concerns novel dibenzo[c,h][1,5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same. 

Dibenzo[c,h][1,5]naphthyridines and their use as DNA probes

The invention relates to new compounds for cancer therapy or diagnosis and to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein-STxB is the Shiga Toxin B subunit or a functional equivalent thereof, -Z(n) wherein n is 0 or 1, Z is an amino-acid residue devoid of sulfydryl groups, or is a polypeptide, -T is a molecule linked by a covalent bound to the S part of Cys, selected from: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1, Y is a linker between T and Cys, which is either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into cells.

Growing community of inventors

Gif-sur-Yvette, France

Jean-Claude Florent